特立帕肽对长节段脊柱融合患者并发症及患者报告结局的影响:基于骨密度的分析
本研究比较接受特立帕肽治疗的骨质疏松患者(OP-T组)与骨量减少患者(OPE组)及骨密度正常患者,按1:2:2匹配,所有患者随访至少2年且后路脊柱融合超过7个固定节段。结果显示OP-T组2年再手术率和症状性假关节率低于OPE组,患者报告结局优于OPE组,且与骨密度正常患者无显著差异。
要点
- 在未匹配队列中,OP-T组2年再手术率(OR=0.45,95%CI:0.20至0.91)和假关节率(OR=0.25,95%CI:0.08至0.61)显著低于OPE组。
- 匹配后,OPE组再手术23.1%(36例)vs OP-T组11.5%(9例)(OR=0.45,p=0.0188);假关节21.8%(34例)vs 6.4%(5例)(OR=0.25,p=0.0048)。
- 匹配后OP-T组与骨密度正常组在2年再手术(OR=0.85,95%CI:0.37至1.98)、假关节(OR=0.51,95%CI:0.181至1.44)和PJK率(OR=0.77,95%CI:0.28至2.06)上无显著差异。
核心结论
- 接受特立帕肽治疗的骨质疏松患者术后2年再手术率和症状性假关节率低于骨量减少患者。
- 接受特立帕肽治疗的骨质疏松患者的患者报告结局和临床结局与骨密度正常患者无差异。
研究设计与样本
- 回顾性匹配队列研究,纳入540例接受后路脊柱融合(>7个固定节段)的成人脊柱畸形患者,随访至少2年。
- OP-T组与OPE组及骨密度正常组按1:2:2比例匹配,匹配后OP-T组78例分别与OPE组156例及骨密度正常组156例比较。
- 主要结局为2年再手术率,次要结局包括假关节伴或不伴内固定失败、近端交界性后凸(PJK)及患者报告结局变化。
主要发现
- 未匹配队列中,OP-T组2年再手术率(OR=0.45,95%CI:0.20至0.91)和假关节率(OR=0.25,95%CI:0.08至0.61)显著低于OPE组。
- 匹配后OP-T组与OPE组比较:再手术11.5%(9例)vs 23.1%(36例)(OR=0.45,p=0.0188);假关节6.4%(5例)vs 21.8%(34例)(OR=0.25,p=0.0048);PJK 7.7%(6例)vs 6.4%(10例)(OR=1.18,p=0.7547)。
- 匹配后OP-T组与骨密度正常组比较:2年再手术OR=0.85(95%CI:0.37至1.98),假关节OR=0.51(95%CI:0.181至1.44),PJK率OR=0.77(95%CI:0.28至2.06),均无显著差异。
- 术后2年,OP-T组患者报告结局优于OPE组。
关键数值与推荐
- 未匹配队列中,OP-T组 vs OPE组:2年再手术率OR=0.45(95%CI:0.20至0.91),假关节率OR=0.25(95%CI:0.08至0.61)。
- 匹配后OP-T组 vs OPE组:再手术11.5%(9例)vs 23.1%(36例),OR=0.45,p=0.0188;假关节6.4%(5例)vs 21.8%(34例),OR=0.25,p=0.0048;PJK 7.7%(6例)vs 6.4%(10例),OR=1.18,p=0.7547。
- 匹配后OP-T组 vs 骨密度正常组:再手术OR=0.85(95%CI:0.37至1.98),假关节OR=0.51(95%CI:0.181至1.44),PJK率OR=0.77(95%CI:0.28至2.06)。
临床怎么用
- 对于接受长节段脊柱融合的骨质疏松患者,使用特立帕肽可能与较低的2年再手术率和症状性假关节率相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgery for adult spinal deformity (ASD) poses substantial risks, including the development of symptomatic pseudarthrosis, which is twice as prevalent among patients with osteoporosis compared with those with normal bone mineral density (BMD). Limited data exist on the impact of teriparatide, an osteoanabolic compound, in limiting the rates of reoperation and pseudarthrosis after treatment of spinal deformity in patients with osteoporosis. METHODS: Osteoporotic patients on teriparatide (OP-T group) were compared with patients with osteopenia (OPE group) and those with normal BMD. OP-T patients were matched with OPE patients and patients with normal BMD at a 1:2:2 ratio. All patients had a minimum 2-year follow-up and underwent posterior spinal fusion (PSF) involving >7 instrumented levels. The primary outcome was the 2-year reoperation rate. Secondary outcomes included pseudarthrosis with or without implant failure, proximal junctional kyphosis (PJK), and changes in patient-reported outcomes (PROs). Clinical outcomes were analyzed using conditional logistic regression. Changes in PROs were analyzed using a mixed-effects model. RESULTS: Five hundred and forty patients (52.6% normal BMD, 32.9% OPE, 14.4% OP-T) were included. In the unmatched cohort, 2-year reoperation rates (odds ratio [OR] = 0.45 [95% confidence interval (CI): 0.20 to 0.91]) and pseudarthrosis rates (OR = 0.25 [95% CI: 0.08 to 0.61]) were significantly lower in the OP-T group than the OPE group. Seventy-eight patients in the OP-T group were matched to 156 patients in the OPE group. Among these matched patients, at 2 years, 23.1% (36) in the OPE group versus 11.5% (9) in the OP-T group had a reoperation (OR = 0.45, p = 0.0188), 21.8% (34) versus 6.4% (5) had pseudarthrosis with or without implant failure (OR = 0.25, p = 0.0048), and 6.4% (10) versus 7.7% (6) had PJK (OR = 1.18, p = 0.7547), respectively. At 2 years postoperatively, PROs were better among OP-T patients than OPE patients. Subsequently, 78 patients in the OP-T group were matched to 156 patients in the normal BMD group. Among these matched patients, there was no significant difference in 2-year reoperation (OR = 0.85 [95% CI: 0.37 to 1.98]), pseudarthrosis (OR = 0.51 [95% CI: 0.181 to 1.44]), and PJK rates (OR = 0.77 [95% CI: 0.28 to 2.06). CONCLUSIONS: Osteoporotic patients on teriparatide demonstrated lower reoperation and symptomatic pseudarthrosis rates 2 years postoperatively compared with osteopenic patients. Moreover, patient-reported and clinical outcomes for osteoporotic patients on teriparatide were not different from those for patients with normal BMD. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Mohanty S, Sardar ZM, Hassan FM, et al. Impact of Teriparatide on Complications and Patient-Reported Outcomes of Patients Undergoing Long Spinal Fusion According to Bone Density. J Bone Joint Surg Am. 2023. PMID: 37973052. doi:10.2106/JBJS.23.00272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。